Metagenomi, Inc. Common Stock
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MGX research report →
Range $7 – $22
Price Chart
About the company
Metagenomi, Inc. operates as a biotechnology company focused on gene editing, committed to developing therapeutic solutions for patients. The company utilizes a distinctive genome editing toolkit, sourced from metagenomics, for its development efforts within the United States.
- CEO
- Jian Irish
- IPO
- 2024
- Employees
- 113
- HQ
- Emeryville, CA, US
Get TickerSpark's AI analysis on MGX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $21.36M
- P/E
- -0.23
- PEG
- 0.05
- P/S
- 3.01
- P/B
- 0.23
- EV/EBITDA
- -0.24
- Div Yield
- 0.00%
- Gross Margin
- 69.48%
- Op Margin
- -1410.57%
- Net Margin
- -1329.31%
- ROE
- -75.04%
- ROIC
- -76.06%
Latest fiscal year · YoY change
- Revenue
- $25.21M-51.8%
- Gross Profit
- $19.89M-62.0%
- Op Income
- $-96,013,000
- Net Income
- $-87,868,000-12.6%
- EPS
- $-2.36-12.9%
- OCF Growth
- +18.5%
- FCF Growth
- +20.3%
- 52W High
- $1.87
- 52W Low
- $0.56
- 50D MA
- $0.90
- 200D MA
- $1.23
- Beta
- 0.67
- RSI (14)
- 24
- Avg Volume
- 163.21K
No earnings-call transcripts are available for MGX yet.
- Free Float
- 67.6%
- Shares Outstanding
- 37.81M
- Float Shares
- 25.57M
of shares held by institutions
43 13F filers
Buy/sell ratio 0.67. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 1.27M | ▲ 28.74K |
| Vanguard Capital Management LLC | 1.08M | 0 |
| Renaissance Technologies LLC | 624.30K | ▼ 118.10K |
| Catalio Capital Management, LP | 528.99K | 0 |
| Two Sigma Investments, LP | 513.70K | ▲ 16.93K |
| Bridgeway Capital Management, LLC | 400.30K | ▲ 4.50K |
| Wells Fargo & Company/Mn | 379.51K | ▲ 177.37K |
| Geode Capital Management, LLC | 275.09K | ▼ 13.58K |
| Pura Vida Investments, LLC | 264.39K | 0 |
| Blackrock, Inc. | 253.24K | ▼ 4.40K |
| Two Sigma Advisers, LP | 201.30K | ▲ 150.90K |
| Vanguard Fiduciary Trust Co | 171.25K | 0 |
Held by 26 ETFs
Biggest fund positions in MGX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 9, 26 | Reid Laurence | buy | 117 |
| Sep 9, 26 | Reid Laurence | buy | 19,883 |
| Sep 8, 26 | Wein Matthew | sell | 358 |
| Sep 8, 26 | Irish Jian | sell | 2,140 |
| Sep 8, 26 | Wapnick Pamela | sell | 1,911 |
| Jun 9, 26 | Reid Laurence | other | 17,400 |
| Jun 9, 26 | Dere Willard H | other | 21,000 |
| Jun 9, 26 | BJERKHOLT ERIC | other | 21,000 |
| Jun 9, 26 | Eckhardt Juergen | other | 21,000 |
| Jun 5, 26 | Wapnick Pamela | sell | 2,884 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our MGX coverage
Recent articles, reports, and earnings notes.
No research on MGX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate MGX report →MGX Resources Limited (MTGRY) Shareholder/Analyst Call Transcript
seekingalpha.com · Nov 18
Metagenomi Therapeutics, Inc. to Present at the Jefferies Global Healthcare Conference in London
globenewswire.com · Nov 11
Metagenomi Therapeutics Announces FDA Clearance of Investigational New Drug Application for MGX-001 and Reports Third Quarter 2026 Financial Results
globenewswire.com · Nov 10
Metagenomi Therapeutics to Present Preclinical Data Supporting MGX-001, a Potential One-Time Therapy for Hemophilia A, in Oral Presentation at 68th American Society of Hematology Annual Meeting
globenewswire.com · Nov 4
Metagenomi Therapeutics, Inc. to Participate in the Chardan 10th Annual Healthcare Conference
globenewswire.com · Oct 13
Reviewing Metagenomi (NASDAQ:MGX) and BioMarin Pharmaceutical (NASDAQ:BMRN)
defenseworld.net · Sep 30
Metagenomi Therapeutics, Inc. to Present at the Wells Fargo 21st Annual Healthcare Conference
globenewswire.com · Sep 1
Did Metagenomi Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
prnewswire.com · Aug 25
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.